<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-130986</identifier>
<setSpec>0210-4806</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Influential Factors in the Response to Salvage Radiotherapy After Radical Prostatectomy</dc:title>
<dc:description xml:lang="en">Objective: To analyze the influential factors in the response in prostatectomized patients with subsequent biochemical relapse (BCR) and treated with salvage radiotherapy (RTP). Material and methods: We analyzed 313 patients with pT2/pT3 prostate cancer who were receiving salvage therapy due to biochemical relapse (from a series of 1,310 radical prostatectomies between 1989-2012). Of the 313 patients; 159 (50.8%) only received androgen deprivation (AD), 63 (20.1%) Radiotherapy (RTP) plus concomitant AD and 91 (29.1%) only RTP. Of these, 57 (62.6%) have maintained complete response and 34 (37.4%) had failure response with post-RTP BCR. Results: Study of the group treated exclusively with salvage RTP. Ninety-one patients were treated with salvage RTP. Median follow-up was 6.4 years and median to recurrence 11 months. Post-RTP biochemical relapse-free survival (PRBRFS) was 68 ± 7% and 30 ± 10% in 5 to 10 years. Median PRBRFS was 7.3 years (6.3-8.3). Initial PSA (HR: 1.08; 95% CI: 1.01-1.1 P = .02) with best PSA cut-off point PSA &gt; 20 ng/ml (HR: 13.6; 95% CI: 2.1-86 P = .005) and PSA pre-RTP (HR: 1.9; 95% CI: 1.2-3.3; P = .009), best PSA cut-off point PSA preRTP 0.92 ng/ml (HR: 4.5; 95% CI: 1.3-15.6; P = .01) showed independent influence in the response in the multivariate study. PRBRFS at 5 years, 81 ± 9% versus 58 ± 9% with initial PSA &lt; 20 or &gt; 20 ng/ml (P = .03). PRBRFS at 5 years, 93 ± 5% versus 53 ± 10% according to PSA pre-RTP &lt; 0.9 or &gt; 0.9 ng/ml (P = .02). Conclusions: In patients treated with salvage RTP after radical prostatectomy, the preoperative PSA &gt; 20 ng/ml and PSA preRTP &gt; 0.92 ng/ml shows an independent influence on the response (AU)</dc:description>
<dc:creator>Hevia, M</dc:creator>
<dc:creator>Tienza, A</dc:creator>
<dc:creator>Rosell, D</dc:creator>
<dc:creator>Algarra, R</dc:creator>
<dc:creator>Pascual, I</dc:creator>
<dc:creator>Robles, J. E</dc:creator>
<dc:creator>Zudaire, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Analizar en los pacientes prostatectomizados con posterior progresión bioquímica (PB) y tratados con radioterapia de rescate (RTP) los factores influyentes en la respuesta. Material y métodos: Analizamos 313 pacientes con cáncer de próstata pT2/pT3 que reciben tratamiento de rescate por PB (de una serie de 1.310 pacientes operados entre 1989-2012). De los 313 pacientes 159 (50,8%) reciben solo deprivación androgénica (DA), 63 (20,1%) radioterapia (RTP) más DA concomitante y 91 (29,1%) solo RTP, de los cuales 57 (62,6%) mantienen respuesta completa y 34 (37,4%) fracaso del tratamiento. Resultados: Estudio del grupo tratado solo con RTP de rescate: 91 pacientes son tratados con RTP de rescate. Mediana de seguimiento 6,4 años. Mediana hasta progresión 11 meses. La supervivencia libre de progresión bioquímica post-RTP (SLPBPR) es de 68 ± 7% y 30 ± 10% en 5 y 10 años y la mediana de SLPBPR 7,3 años (6,3-8,3). En el análisis multivariado presentan influencia independiente en la respuesta: el PSA inicial (HR: 1,08; IC 95%: 1,01-1,1; p = 0,02) con mejor punto de corte PSA &gt; 20 ng/ml (HR: 13,6; IC 95%: 2,1-86; p = 0,005) y PSA pre-RTP (HR: 1,9; IC 95%: 1,2-3,3 p=0,009), mejor punto de corte PSA preRTP de 0,92 ng/ml (HR: 4,5; IC95% 1,3-15,6; p = 0,01). SLPBPR a 5 años 81 ± 9% frente a 58 ± 9% con PSA inicial &lt; 20 o &gt; 20 ng/ml (p=0,03). SLPBPR a 5 años 93 ± 5% frente a 53 ± 10% según PSA pre-RTP &lt; 0,9 o &gt; 0,9 ng/ml (p = 0,02). Conclusiones: En los pacientes prostatectomizados tratados con RTP de rescate el PSA preoperatorio &gt; 20 ng/ml y el PSA preRTP &gt; 0,92 ng/ml tienen influencia independiente en la respuesta (AU)</dc:description>
<dc:source>Actas Urol Esp;38(10): 662-668, dic. 2014. tab, graf</dc:source>
<dc:identifier>ibc-130986</dc:identifier>
<dc:title xml:lang="es">Factores influyentes en la respuesta al rescate con radioterapia tras prostatectomía radical</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d24373^s22002</dc:subject>
<dc:subject>^d11911^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d11914^s22059</dc:subject>
<dc:subject>^d30596^s22002</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d32285</dc:subject>
<dc:subject>^d9557^s22053</dc:subject>
<dc:type>article</dc:type>
<dc:date>201412</dc:date>
</metadata>
</record>
</ibecs-document>
